Our successful multi-year target identification collaboration with leading pharmaceutical company AstraZeneca tackles some of the world’s most complex diseases.
Our collaboration optimises target identification, combining our BenAI Engine and our end-to-end drug discovery solutions with AstraZeneca’s data and disease expertise.
Our teams work side by side to uncover new insights into complex biology and predict novel targets that specifically treat the underlying cause of disease.
AstraZeneca is now progressing four of the most promising targets out of the five initially selected into the AstraZeneca portfolio in chronic kidney disease (CKD) and IPF.
The vast amount of data available to research scientists is growing exponentially each year. By combining AstraZeneca’s disease area expertise with BenevolentAI’s leading AI capabilities, we can unlock the potential of this wealth of data to improve our understanding of complex disease biology and identify new targets.
Progress so far
Oct 6, 2022
May 17, 2022
Jan 13, 2022
We partner with leading pharmaceutical and biotech companies to help them unlock biological insights and tackle complex therapeutic challenges.